Thanks again, Skint. On the Stamler's paper page 7 there is presented the chemical structure of PBT434 and as you may know it is a quinazolinone as is mdivi-1. In the first paper of mdivi-1 the authors Cassidy-Stone et al ( posted below) have tested different quinazolinones in their ability to inhibit mitochondrial division. The chemical structures of these were classified as full efficacy, moderate efficacy and poor efficacy. So there are many quinazolinones which have poor effect in inhibiting mitochondrial division but I think that our PBT434 belongs to those quinazolinones with at least moderate efficacy in this inhibition.
The paper itself is good reading if you want to understand how mdivi-1 ( and possibly PBT434) works in mitochondria. The paper tells: "These data indicate the mitochondrial division dynamin directly regulates mitochondrial outer membrane permeabilization independent of Drp1-mediated division. Our findings raise the interesting possibility that mdivi-1 represents a novel class of therapeutics for stroke, myocardial infarction, and neurodegenerative diseases
".
Here is the almost 11 y old Cassidy-Stone paper with the chemical structures to compare PBT434 and mdivi-1. https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2267902/
I only wonder how Prana ever came to select a quinazolinone for their initial studies and then added to that structure something that it started to work also as an iron chelator and not only as a mitochondrion division inhibitor. Or did everything happen in an other oder as it looks according the published PBT434 paper.